Philip C. Trackman, PhD
Emeritus Professor
Boston University Henry M. Goldman School of Dental Medicine
Translational Dental Medicine

PhD, Boston University
BA, College of Wooster



Dr. Philip Trackman is an Emeritus Professor in the Department of Translational Dental Medicine at the Boston University Henry M. Goldman School of Dental Medicine. Dr. Trackman is also an important member of the Oral Cancer Research Initiative (OCRI) and is currently investigating the molecular mechanisms of the connective tissue enzyme, lysyl oxidase, and its potential therapeutic effects in oral cancer. A third area of interest is mechanisms of diabetic bone disease, in which he has recently provided evidence for dysregulation of osteoblast lysyl oxidase by gastric hormones in diabetes to be a determining mechanism in this pathology.

Dr. Trackman became interested in cancer research in 1990, after cloning lysyl oxidase for the very first time. This enzyme family has tumor inhibitory properties and also enhances tissue fibrosis and metastasis. In the context of the OCRI, Dr. Trackman is working to investigate the two therapeutic opportunities which these findings suggest. His first aim is to explore how to inhibit the harmful activity of the active enzymes, while taking advantage of the tumor growth inhibitory activity of the lysyl oxidase propeptide. The lysyl oxidase propeptide was shown by Dr. Trackman’s lab in 2004 to be responsible for the tumor growth inhibitory properties of lysyl oxidase. His lab has confirmed this in animal models of both breast and prostate cancer, and recently also in oral cancer. Dr. Trackman collaborated on this project with Research Assistant Professor Dr. Manish Bais, who is also an OCRI investigator.

Dr. Trackman’s ongoing research will establish the extent to which new and powerful lysyl oxidase family enzyme activity inhibitors can block human oral cancer tumor growth and/or metastasis in mice. This work is funded by the OCRI’s Etiology and Pathogenesis of Oral Cancer Affinity Research Collaborative (ARC) as a part of Boston University’s Evans Center for Interdisciplinary Biomedical Research. In addition, modifications to the structure of the lysyl oxidase propeptide are underway with the goal of enhancing its tumor growth inhibitory properties, and also to identify its most important binding partners in its ability to inhibit tumor growth.

Director of Graduate Programs, Molecular & Cell Biology
Boston University Henry M. Goldman School of Dental Medicine
Molecular & Cell Biology


Research Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Biochemistry & Cell Biology


Member
Boston University
BU-BMC Cancer Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Member
Boston University
Genome Science Institute


Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences




Mechanism of Bone Marrow Neoplasm-Induced Osteosclerosis
05/01/2018 - 04/30/2020 (Multi-PI)
PI: Philip C. Trackman, PhD
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5R21AR072748-02

Lysyl Oxidase Dysregulation in Diabetic Bone Disease
08/16/2016 - 08/15/2018 (Key Person / Mentor)
PI: Eileen Daley
NIH/National Institute of Dental & Craniofacial Research
5F31DE026685-02

Biological Activit of Lysyl Oxidase Like-2 Inhibitors
04/01/2015 - 12/31/2017 (PI)
Pharmaxis


Cellular or Extracellular Targeting of Lysyl Oxidase Propeptide for Oral Cancer
07/01/2014 - 06/30/2017 (PI)
NIH/National Institute of Dental & Craniofacial Research
5R21DE023973-02

Inhibited Intramembraneous Bone Healing in Diabetes
03/01/2009 - 01/31/2016 (PI)
NIH/National Institute of Dental & Craniofacial Research
5R01DE014066-10

Growth Factors and Gingival Fibrosis
04/01/1994 - 06/30/2012 (PI)
NIH/National Institute of Dental & Craniofacial Research
5 R01 DE11004 15

Lysyl Oxidase Inhibition of Ras-Mediated Transformation
09/01/1999 - 04/30/2010 (Co-PI)
NIH/National Cancer Institute
5 R01 CA82742 10

Mechanisms of Mineralized Matrix Accumulation
02/01/1999 - 01/31/2004 (PI)
NIH/National Institute of Dental & Craniofacial Research
5 R01 DE12209 04

Screen Fibrogen anti-CTGF Antibodies for Blocking Activity
05/15/2001 - 05/14/2002 (PI)
FibroGen Inc

Phenotypic Reversion Requires Lysyl Oxidase mRNA
09/15/1998 - 09/14/2000 (PI)
NIH/National Institute of Dental & Craniofacial Research
5 R03 DE12425 02



Title


Yr Title Project-Sub Proj Pubs
2024 Mechanism of lysyl oxidase propeptide in oral squamous cell carcinoma microenvironments 1R56DE033090-01A1
2022 Osteoblast Dopamine Receptor Mediates Diabetic Bone Disease 5R21AR077260-02
2021 Osteoblast Dopamine Receptor Mediates Diabetic Bone Disease 1R21AR077260-01A1
2019 Mechanism of Bone Marrow Neoplasm-Induced Osteosclerosis 5R21AR072748-02 1
2018 Mechanism of Bone Marrow Neoplasm-Induced Osteosclerosis 1R21AR072748-01 1
2015 Cellular or Extracellular Targeting of Lysyl Oxidase Propeptide for Oral Cancer 5R21DE023973-02 8
2014 Cellular or Extracellular Targeting of Lysyl Oxidase Propeptide for Oral Cancer 1R21DE023973-01A1 8
2013 Inhibited Intramembranous Bone Healing in Diabetes 5R01DE014066-10 31
2012 Inhibited Intramembranous Bone Healing in Diabetes 5R01DE014066-09 31
2011 Inhibited Intramembranous Bone Healing in Diabetes 5R01DE014066-08 31
Showing 10 of 42 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Karagianni A, Karkempetzaki AI, Brooks D, Matsuura S, Dambal V, Trackman PC, Ravid K. Deletion of mouse lysyl oxidase in megakaryocytes affects bone properties in a sex-dependent manner. Blood. 2024 Jun 20; 143(25):2666-2670.View Related Profiles. PMID: 38635757; DOI: 10.1182/blood.2024024620;
     
  2. Peymanfar Y, Mahjour F, Shrestha N, de la Cueva A, Chen Y, Huang S, Kirsch KH, Han X, Trackman PC. The Lysyl Oxidase G473A Polymorphism Exacerbates Oral Cancer Development in Humans and Mice. Int J Mol Sci. 2023 May 28; 24(11).View Related Profiles. PMID: 37298359; DOI: 10.3390/ijms24119407;
     
  3. Trackman PC. Multifunctional Lysyl Oxidases. Int J Mol Sci. 2023 Mar 23; 24(7). PMID: 37047014; DOI: 10.3390/ijms24076044;
     
  4. Trackman PC, Peymanfar Y, Roy S. Functions and Mechanisms of Pro-Lysyl Oxidase Processing in Cancers and Eye Pathologies with a Focus on Diabetic Retinopathy. Int J Mol Sci. 2022 May 03; 23(9).View Related Profiles. PMID: 35563478; DOI: 10.3390/ijms23095088;
     
  5. Daley EJ, Trackman PC. ß-Catenin mediates glucose-dependent insulinotropic polypeptide increases in lysyl oxidase expression in osteoblasts. Bone Rep. 2021 Jun; 14:101063.View Related Profiles. PMID: 33981809; DOI: 10.1016/j.bonr.2021.101063;
     
  6. Kim D, Lee D, Trackman PC, Roy S. Effects of High Glucose-Induced Lysyl Oxidase Propeptide on Retinal Endothelial Cell Survival: Implications for Diabetic Retinopathy. Am J Pathol. 2019 10; 189(10):1945-1952.View Related Profiles. PMID: 31537300; DOI: 10.1016/j.ajpath.2019.06.004;
     
  7. Daley EJ, Pajevic PD, Roy S, Trackman PC. Impaired Gastric Hormone Regulation of Osteoblasts and Lysyl Oxidase Drives Bone Disease in Diabetes Mellitus. JBMR Plus. 2019 Oct; 3(10):e10212.View Related Profiles. PMID: 31687648; DOI: 10.1002/jbm4.10212;
     
  8. Lee VS, Halabi CM, Broekelmann TJ, Trackman PC, Stitziel NO, Mecham RP. Intracellular retention of mutant lysyl oxidase leads to aortic dilation in response to increased hemodynamic stress. JCI Insight. 2019 06 18; 5. PMID: 31211696; DOI: 10.1172/jci.insight.127748;
     
  9. Mahjour F, Dambal V, Shrestha N, Singh V, Noonan V, Kantarci A, Trackman PC. Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB. Oncogenesis. 2019 May 13; 8(5):34.View Related Profiles. PMID: 31086173; DOI: 10.1038/s41389-019-0144-0;
     
  10. de la Cueva A, Emmerling M, Lim SL, Yang S, Trackman PC, Sonenshein GE, Kirsch KH. A polymorphism in the lysyl oxidase propeptide domain accelerates carcinogen-induced cancer. Carcinogenesis. 2018 07 03; 39(7):921-930.View Related Profiles. PMID: 29579155; DOI: 10.1093/carcin/bgy045;
     
Showing 10 of 118 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 116 publications over 38 distinct years, with a maximum of 7 publications in 2006 and 2007 and 2010 and 2015

YearPublications
19801
19812
19832
19841
19881
19891
19902
19914
19923
19933
19952
19962
19981
19992
20001
20012
20022
20033
20046
20053
20067
20077
20084
20093
20107
20115
20122
20135
20144
20157
20163
20176
20183
20194
20211
20221
20232
20241


2013 PloS One: Academic Editor
1997-2011 Listed in Marquis Who’s Who in Science and Engineering
1981-1983 Brandeis University: American Cancer Society Postdoctoral Fellow
1977-1980 Boston University School of Medicine: Predoctoral NIH Traineeship
1975 American Chemical Society : Outstanding Senior Award
Contact for Mentoring:

700 Albany St Ctr for Adv Biomed Res
Boston MA 02118
Google Map


Trackman's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department